MedPath

Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4

Completed
Conditions
Colon Cancer
Interventions
Other: Chimio-oncogramme
Registration Number
NCT02305368
Lead Sponsor
University Hospital, Limoges
Brief Summary

In patients with colonic adenocarcinoma stage 4 which are potentially resectable metastases (lung and liver metastases), treatment with chemotherapy is necessary but not end in success in 10% of cases. The development of techniques for administering personalized treatment becomes necessary for these patients. Thus, in vitro tests on cells from tumors of these patients and evaluating the effect of chemotherapy on these could be made for each patient. In France, the company develops Oncomedics these tests.

This is a pilot study that will make a first evaluation under actual conditions of chimio-oncogramme.

Detailed Description

A fragment of colon tumors will be taken from a specimen or a cold biopsy, tissue from patients diagnosed with colon carcinoma metastatic (stage 4). In parallel and systematically: analysis by the pathologist of a histological section.

* Culturing the cells obtained from the tumor by Oncomedics fragment in a defined medium and provided for enriching tumor cells compared to stromal cells.

* Maintaining the cells in culture for 7 days.

* Effects of conventional chemotherapy (corresponding to protocols) on these cells for 72 hours (growth chambers) by Oncomedics (chimio-oncogramme).

* For each chemotherapy tested, measuring the proportion of dead cells / total cells.

* Retained by Oncomedics results, not given to the nursing team. The patient will be treated and followed up in the usual way.

* At the end of the study, comparing the in vitro results (chimio-oncogramme) to the patient's response to (x) the same (s) chemotherapy (s).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • patient with adenocarcinoma of the colon diagnosed at stage 4 receiving standard therapy
  • targets must be measurable tumor lesions (RECIST)
  • patient has not expressed opposition to the use of their residual tumor
Exclusion Criteria
  • Against-formal indication to an indispensable para-clinical examination of the patient monitoring
  • Use of chemotherapy, hormone therapy or concomitant radiotherapy
  • Cons-indication for chemotherapy
  • Are pregnant, nursing or lack of contraception for women of childbearing age.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
OncogrammeChimio-oncogrammeTaking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
Primary Outcome Measures
NameTimeMethod
In vitro analysis of chemotherapy responses7 days

Evaluate the predictive value of chemo-oncogramme on the patient's response to the same (s) chemotherapy (s)

Secondary Outcome Measures
NameTimeMethod
quality of life7 days

Evaluate the predictive value of chemo-oncogramme on chemical toxicity and quality of life of patients.

© Copyright 2025. All Rights Reserved by MedPath